This phase I study seeks to understand the safety of a new drug (ADG126) in people with cancers that are advanced and/or have spread to other parts of the body (metastatic).
This trial is treating patients with advanced and/or metastatic cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
First-in-human (FIH), Open-Label, Phase I Dose Escalation Study of ADG126 in Patients With Advanced Malignancies
This is a non-randomised trial with 5 experimental arms. Each experimental arm involves participants receiving ADG126 (an anti -CTLA-4 fully human monoclonal antibody) intravenously(IV) over a period of 60-90 minutes. Each Experimental Arm receives different dose levels of ADG126. ADG126 will be administered IV over 60-90 minutes with planned doses every three weeks for the first 4 cycles. If no intolerable toxicities occur during the first consecutive 4 treatment cycles, administration of ADG126 may continue every 3 weeks for up to 2 years per agreement with investigator and/ or the treating team.
Recruiting Hospitals Read More